DEF 14A: Verve Therapeutics Sets Date for 2024 Annual Stockholders Meeting

Verve Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, auditor ratification, executive compensation, and other matters.

Summary

• Verve Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on June 6, 2024, at 9:00 a.m. Eastern Time, as a virtual meeting.
• Stockholders of record as of April 11, 2024, are eligible to vote on the election of two Class III directors, ratification of Ernst & Young LLP as the independent accounting firm, an advisory vote on executive compensation, and the frequency of future advisory votes on executive compensation.
• The Board of Directors recommends voting in favor of all proposals.
• Proxy materials are available online, and a Notice of Internet Availability of Proxy Materials was mailed to stockholders on or about April 26, 2024.
• Stockholders can vote online, by telephone, or by mail, with specific deadlines for each method.
• The company's board consists of seven members divided into three classes with staggered three-year terms.
• The nominees for Class III directors are Burt Adelman, M.D., and Sekar Kathiresan, M.D.
• The board has determined that all directors except Dr. Kathiresan are independent.
• The company has established an audit committee, a compensation committee, and a nominating and corporate governance committee.
• The company has adopted an anti-hedging policy and a clawback policy.
• The company's executive compensation program includes competitive salaries, cash bonuses, and equity-based compensation.
• The company maintains equity incentive plans, including the 2018 Equity Incentive Plan, the 2021 Stock Incentive Plan, and the Amended and Restated 2021 Employee Stock Purchase Plan.
• The company has entered into employment agreements with its named executive officers, providing for certain payments upon termination or change in control.
• The company has engaged in certain transactions with related persons, including a collaboration and license agreement with Beam Therapeutics and participation in a public offering by an entity affiliated with GV.
• The company has adopted policies and procedures for the review of related person transactions.
• Stockholder proposals for the 2025 proxy statement must be received by December 27, 2024.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The board recommends voting for all proposals, indicating a positive outlook from management's perspective.

Positives

• The company is providing stockholders with multiple avenues to vote, including online, by telephone, and by mail.
• The board is recommending that stockholders vote in favor of all proposals.
• The company has established key committees to oversee important aspects of its operations, including audit, compensation, and corporate governance.
• The company has adopted policies to promote ethical behavior and responsible compensation practices, including an anti-hedging policy and a clawback policy.
• The company is committed to transparency and has adopted policies and procedures for the review of related person transactions.

Risks

• The document does not explicitly mention any specific risks.
• However, the document does mention that the company faces a number of risks, including those described under Risk Factors in our 2023 Annual Report.

Future Outlook

The board of directors will take into consideration the outcome of the advisory vote on the frequency of future advisory votes on executive compensation in making a determination about the frequency of future executive compensation advisory votes. The company expects to begin offerings to its eligible employees to purchase stock under the 2021 ESPP on each June 1 and December 1 (or the next following business day).

Management Comments

• The board of directors recommends that you vote in favor of each of these proposals as outlined in the accompanying proxy statement.
• Our executive compensation program embodies a pay-for-performance philosophy that supports our business strategy and seeks to align the interests of our executive officers with our stockholders.
• The board of directors believes that an annual executive compensation advisory vote will facilitate more direct stockholder input about executive compensation.

Industry Context

Verve Therapeutics is operating in the biotechnology/pharmaceutical industry, which is characterized by high levels of innovation, competition, and regulation. The company's collaboration with Beam Therapeutics and its focus on gene editing technologies are indicative of the industry's trend towards developing novel therapies for cardiovascular diseases.

Comparison to Industry Standards

• The document mentions that the compensation committee considers compensation data for national and regional companies in the biotechnology/pharmaceutical industry provided by its independent compensation consultant to help guide its executive compensation decisions.
• The document also mentions that the company's compensation recovery policy is in accordance with Nasdaq Listing Rule 5608, which implements Rule 10D-1 under the Exchange Act.
• The document does not provide specific comparisons to comparable companies or projects.

Corporate Governance

Related Party Transactions

• Collaboration and license agreement with Beam Therapeutics.
• Participation in public offering by an entity affiliated with GV.
• Registration rights agreement with certain stockholders.
• Indemnification agreements with directors and executive officers.

Stakeholder Impact

• Shareholders: The document provides information relevant to their voting decisions and the governance of the company.
• Employees: The document outlines compensation policies and benefit plans.
• Directors and Executive Officers: The document details their roles, responsibilities, and compensation.
• Customers: The document does not directly impact customers.
• Suppliers: The document does not directly impact suppliers.
• Creditors: The document does not directly impact creditors.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and will publish final voting results in a Current Report on Form 8-K.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, audit committee, stockholders, Verve Therapeutics, governance